GlassScriptPhysician profile
Michael Bauguess
NPI 1912986647
$16,588.39
in general payments reported to CMS, 2019-2025
38 companies · $4,133 in 2025
The $4,133 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,852 · 2022: $1,999 · 2023: $3,791 · 2024: $4,814 · 2025: $4,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Travel and Lodging: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,461.50 |
| Travel and Lodging | $275.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,692.71 | 2021-2025 | Epclusa, Biktarvy, Sunlenca |
| Viiv Healthcare Company | $2,271.64 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Janssen Scientific Affairs, LLC | $1,339.87 | 2021 | |
| Merck Sharp & Dohme LLC | $1,233.22 | 2022-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $1,091.77 | 2022-2025 | |
| Amgen INC. | $824.91 | 2022-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $669.78 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $526.71 | 2021-2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $506.56 | 2022-2024 | Caplyta |
| Pfizer INC. | $409.73 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $396.35 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $323.12 | 2022-2025 | Tezspire |
| Vanda Pharmaceuticals INC. | $316.15 | 2024-2025 | Fanapt |
| Daiichi Sankyo INC. | $311.15 | 2023-2025 | Injectafer |
| Emd Serono, INC. | $279.55 | 2023-2025 | Serostim |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $232.15 | 2023-2025 | Rexulti |
| Genzyme Corporation | $218.49 | 2024-2025 | |
| Medtronic, INC. | $198.97 | 2022-2023 | Venaseal |
| Lilly USA, LLC | $176.16 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Braeburn INC. | $165.14 | 2025 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.81 | 2022-2025 | |
| Glaxosmithkline, LLC. | $151.09 | 2022-2025 | Nucala, Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $141.22 | 2023 | Quviviq |
| Stryker Corporation | $124.80 | 2024 | Infinity Adaptis |
| Janssen Pharmaceuticals, INC | $122.73 | 2022-2023 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $118.74 | 2025 | |
| Janssen Products, LP | $99.00 | 2022 | |
| Abbott Laboratories | $93.50 | 2025 | Jot Dx |
| Indivior INC. | $73.76 | 2022-2025 | Sublocade |
| Viatris Specialty LLC | $66.36 | 2025 | Yupelri |
| Exact Sciences Corporation | $60.55 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $42.99 | 2022 | |
| Phathom Pharmaceuticals, INC. | $42.25 | 2025 | Voquezna |
| Sanofi Pasteur INC. | $26.36 | 2025 | |
| Collegium Pharmaceutical, INC. | $23.79 | 2022 | |
| Theratechnologies INC. | $21.71 | 2023 | Egrifta, Trogarzo |
| Eisai INC. | $21.49 | 2022 | |
| Scilex Pharmaceuticals INC. | $19.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bauguess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.